Centrum Medyczne ENEL-MED S.A.

As of March 31, 2026, Centrum Medyczne ENEL-MED S.A. carries a market capitalization of 540.15M, placing it among publicly traded companies globally. Its enterprise value stands at 846.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Centrum Medyczne ENEL-MED S.A.'s next confirmed earnings release is scheduled for December 2, 2026.

As of March 31, 2026, Centrum Medyczne ENEL-MED S.A. has 28.28M shares outstanding.

As of March 31, 2026, Centrum Medyczne ENEL-MED S.A. trades at a trailing price-to-earnings ratio of 73.23. The price-to-sales ratio is 0.64, and the price-to-book ratio stands at 2.89.

As of March 31, 2026, Centrum Medyczne ENEL-MED S.A. trades at an EV/EBITDA multiple of 7.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.01 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Centrum Medyczne ENEL-MED S.A. trades at an EV/FCF ratio of 22.40, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 846.22M versus a market cap of 540.15M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Centrum Medyczne ENEL-MED S.A. maintains a current ratio of 0.62, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 188.25, indicating elevated leverage, while an interest coverage ratio of 6.00 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Centrum Medyczne ENEL-MED S.A. posted a return on equity (ROE) of 4.22, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.08 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.29, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.44, useful for judging operating efficiency across full business cycles. The company generates approximately 735,597.01 in revenue per employee across its workforce of 1,203.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 187.20 indicates how many times Centrum Medyczne ENEL-MED S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Centrum Medyczne ENEL-MED S.A. recorded 2.10M in income tax expense. That works out to an effective tax rate of 21.39, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 9.81M, leaving 7.71M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Centrum Medyczne ENEL-MED S.A.'s stock has gained approximately 12.85% over the past 52 weeks. The 50-day moving average sits at 20.17, while the 200-day moving average is 20.08.

Over the twelve months ended March 31, 2026, Centrum Medyczne ENEL-MED S.A. generated 885.29M in revenue and converted that into 7.71M in net income, yielding earnings per share of 0.26. EBITDA reached 108.93M, while operating income came in at 23.38M.

As of March 31, 2026, Centrum Medyczne ENEL-MED S.A. holds 45.36M in cash and equivalents against 351.43M in total debt, resulting in a net debt position of -15.03M. Total book value stands at 186.69M, with working capital of -65.40M providing operational flexibility.

Centrum Medyczne ENEL-MED S.A. produced 124.61M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -101.11M in capital expenditures, free cash flow totaled 23.50M - equivalent to 0.79 per share.

Over the twelve months ended March 31, 2026, Centrum Medyczne ENEL-MED S.A. posted a gross margin of 9.45, reflecting its pricing power and cost economics. The operating margin of 2.64 and net profit margin of 0.87 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 4.16, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.00, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Centrum Medyczne ENEL-MED S.A. shareholders.

As of March 31, 2026, Centrum Medyczne ENEL-MED S.A. has an Altman Z-Score of 2.23, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.